Table 2:

Number of participants included in the original study and the follow-up study

Group	Original study		Follow-up study
	Enrolled (Oxford)*	Completed (Oxford)*	At baseline			At 1 mo	At 2 mo	At 3 mo
			Enrolled	Included in ITT analysis for persistence†	Received first dose	Included in ITT analysis for immunogenicity†	Received second dose	Included in ITT analysis for immunogenicity†
4CMenB246-12‡	50 (46)	45 (41)	19	17	19	19	NA	NA
rMenB246-12§	48 (44)	44 (40)	29	29	29	28	NA	NA
4CMenB-12¶	24 (22)	23 (21)	8	8	8	7	8	8
rMenB-12**	25 (23)	24 (23)	14	14	14	13	14	13
Control††	NA	NA	43	40	42	38	41	36

4CMenB = multicomponent serogroup B meningococcal vaccine, ITT = intention-to-treat, NA = not applicable, rMenB = recombinant protein serogroup B meningococcal vaccine.

^*Because the follow-up study was a single-centre study, only participants recruited from Oxford (in parentheses) in the original study were invited to participate in the follow-up study.

^†Exclusions from the ITT analysis are due to lack of evaluable serum sample, except for 1 participant in the control group who withdrew consent.

^‡Participants who received 4 doses of 4CMenB vaccine at 2, 4, 6 and 12 months.

^§Participants who received 4 doses of rMenB vaccine at 2, 4, 6 and 12 months.

^¶Participants who received 1 dose of 4CMenB at 12 months.

^**Participants who received 1 dose of rMenB vaccine at 12 months.

^††Participants with no previous exposure to 4CMenB or rMenB vaccines.